Changes in risk factor status and risk of future ASCVD events in

primary prevention

In-Chang Hwang, MD[a,b], Chee Hae Kim, MD[c], Jae-Young Kim, MS[d],

Jiesuck Park, MD[a], Hye Jung Choi, MD[a], Hong-Mi Choi, MD[a,b],

Yeonyee E. Yoon, MD, PhD[a,b], Goo-Yeong Cho, MD, PhD[a,b]

[a]Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul

National University Bundang Hospital, Seongnam, Gyeonggi, South Korea

[b]Department of Internal Medicine, Seoul National University College of Medicine, Seoul,

South Korea

[c]Veteran Health Service Medical Center, Seoul, South Korea

[d]Department of Statistics, Soonchunhyang University Bucheon Hospital, Gyeonggi, South

Korea

Short title: Risk factor status change and ASCVD risk

Word count: 876 words

Keywords: atherosclerotic cardiovascular disease; primary prevention; risk factor

Acknowledgments: We thank Professor Jeong-Ju Yoo, MD, PhD, for her dedication and

support of this study.

Sources of funding: None.

Disclosures: None.

Address for correspondence:

In-Chang Hwang, MD

Associate Professor

Division of Cardiology, Department of Internal Medicine

Seoul National University Bundang Hospital

82 Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, South Korea

Tel.: +82-31-787-7065 / Fax: +82-31-787-4290

E-mail: inchang.hwang@gmail.com

Abstract

Primary cardiovascular prevention highlights the management of risk factors through lifestyle changes and therapeutic interventions. While most previous studies focused on the presence of risk factors assessed only at baseline, temporal changes in the risk factor status were not considered. We aimed to evaluate the prognostic impact of temporal changes in risk factor status in primary prevention settings. A population-based cohort of 211,077 individuals who underwent repetitive 10-year atherosclerotic cardiovascular disease (ASCVD) risk assessments over 4–5 years, was identified from National Health Insurance Services claims data of South Korea. Changes in risk-factor status for blood pressure, glycemic control, cholesterol levels, smoking status, body-mass index, and physical activity were assessed. Hazard ratios (HR) for ASCVD events after follow-up screening were calculated based on increased or decreased risk factors between baseline and follow-up. Regardless of baseline status, increased risk factors correlated with higher future ASCVD risk, while a decrease corresponded to a lower risk. Notably, individuals initially without risk factors but developing three at follow-up faced significantly higher ASCVD risk (adjusted HR 2.74, 95% CI: 1.31–5.76). Conversely, those decreasing three risk factors from 5 or 6 exhibited almost a 50% reduction in ASCVD risk. These findings show that primary prevention effects can be reflected by changes in risk factor status, underscoring the need to monitor temporal changes in risk factors for effective primary prevention.

Keywords: atherosclerotic cardiovascular disease; primary prevention; risk factor

Main text

In clinical practice, primary prevention targets cardiovascular risk factors through lifestyle

changes and therapeutic interventions, which can alter risk factor status over time and affect

prognosis.(1) While prior studies typically assessed risk factors only at baseline, neglecting

temporal changes,(2, 3) our recent publication demonstrated a significant correlation between

the rate of change in 10-year ASCVD risk (Δ10-year ASCVD risk/year) and future ASCVD

events, irrespective of baseline risk profiles.(4) Although changes in the 10-year ASCVD risk

reflect overall risk management, real-world practice more prioritizes on controlling individual

risk factors such as hypertension, diabetes, dyslipidemia, smoking status, physical activity,

and obesity. Monitoring the occurrence or resolution of these risk factors is more intuitive for

both physicians and patients than tracking changes in the 10-year ASCVD risk scores.

Therefore, we aimed to assess the prognostic impact of temporal changes in risk factor status

in primary prevention settings.

Data from the National Health Insurance Services (NHIS) Health Screening Cohort

of South Korea, a nationwide claims database, were used.(4, 5) This study was approved by

the institutional review board of Seoul National University Bundang Hospital and adhered to

the 2013 revised Declaration of Helsinki. Among 1,108,369 individuals who participated in

the screening program between 2009 and 2015, we excluded those without repeated

screenings at a 4–5 year interval and those without sufficient data to assess changes in risk

factors. Additionally, individuals with established ASCVD, malignancy, or end-stage renal

disease were excluded. A total of 211,077 individuals were analyzed. The primary outcome

was ASCVD events (myocardial infarction, acute coronary syndrome, stable or unstable

angina, coronary revascularization, stroke, transient ischemic attack, or peripheral arterial

disease) occurring after follow-up screening (4–5 years post baseline screening, until 2019).

Changes in risk-factor status between baseline and follow-up screenings were assessed for 6

components: blood pressure (≥140/90 mmHg), glycemic control (fasting glucose of ≥130

mg/dL for diabetic patients; occurrence of diabetes for non-diabetic patients), low-density

lipoprotein cholesterol level (≥160 mg/dL), smoking status (current smoking), body-mass

index (≥25 mg/kg^2), and physical activity. Appropriate physical activity was defined as at

least 150 min of moderate-intensity exercise or 75 min of weekly vigorous-intensity

exercise.(1) To determine the resolution of specific diseases (e.g., hypertension, diabetes,

dyslipidemia), we examined claims for diagnostic codes and medications at follow-up

screenings. Patients initially diagnosed but lacking these indicators at follow-up prompted

further assessment of blood pressure, fasting glucose, and lipid profiles. Resolution was

confirmed when diagnostic codes, medications, and screening measurements were all

negative at follow-up. Study population was stratified based on the number of risk factors at

baseline. Hazard ratios (HR) for ASCVD events occurring after the follow-up screenings

were calculated according to changes in the number of risk factors between baseline and

follow-up screenings. Multivariable Cox proportional hazard regression model was used,

adjusting for age, sex, smoking status, presence of diabetes, total cholesterol, high-density

lipoprotein cholesterol, systolic blood pressure, and treatment for hypertension. For

subgroups with small number of patients, Cox proportional hazard models with Firth's

penalized likelihood procedures were applied. For patients initially presenting with 0, 1, or 2

risk factors, HR was calculated based on the increase in risk factors, using those with the

lowest number of risk factors at follow-up as the reference group. Conversely, for patients

with 3, 4, or 5–6 risk factors at baseline, HR was calculated based on a decrease in risk

factors, with those having the highest number of risk factors at follow-up as the reference

group.

Regardless of baseline risk factor status, an increase in risk factors correlated with

higher ASCVD event risk, while a decrease corresponded to lower risk (**Figure**). Among

individuals without any risk factors at baseline, those with 3 risk factors at follow-up had a

higher risk of future ASCVD events (adjusted HR 2.74, 95% confidence interval: 1.31–5.76),

compared to those with no change in risk factor status (no risk factors at both baseline and

follow-up examinations). Similar trend was observed among individuals with poor risk factor

control at baseline. Compared to those with 5 or 6 risk factors at both baseline and follow-up

examinations, individuals with a decrease of 3 risk factors had reduced risk of ASCVD events

by nearly 50%.

115   Several limitations should be acknowledged in this study. Firstly, we relied on a

claims database within a population-based cohort, potentially introducing selection bias

despite the extensive coverage of the NHIS.(4, 5) Secondly, we did not assess the impact of

medications in our analyses. Thirdly, small sample sizes with rare events in certain subgroups

limited statistical significance, even with Firth's penalized likelihood procedures. Finally, it's

important to note that each risk factor may carry a different prognostic weight, introducing

limitations in our approach.

122   Nevertheless, this is the first population-based cohort study focusing on the temporal

changes in cardiovascular risk factors in primary preventive setting. Unlike calculating

changes in 10-year ASCVD risk estimates,(4) this approach provides practical evidence

supporting risk factor control. Specifically, we demonstrated that primary prevention effects

can be reflected by changes in risk factor status. Among individuals with appropriate risk

factor control at baseline, newly developed risk factors significantly increase ASCVD events

risk. Conversely, even in individuals with poor risk factor control at baseline, appropriate

management can significantly improve prognosis. These findings emphasize the pivotal

prognostic role of managing each risk factor in real-world practice.

References

1.   Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al.

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of

the American College of Cardiology/American Heart Association Task Force on Clinical

Practice Guidelines. Circulation. 2019;140(11):e596-e646. Epub 2019/03/19. doi:

10.1161/CIR.0000000000000678. PubMed PMID: 30879355; PubMed Central PMCID:

PMCPMC7734661.

2.   Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk

Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J

Med. 2018;379(7):633-44. Epub 2018/08/16. doi: 10.1056/NEJMoa1800256. PubMed PMID:

30110583.

3.   Wright AK, Suarez-Ortegon MF, Read SH, Kontopantelis E, Buchan I, Emsley R, et

al. Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in

Primary and Secondary Prevention Settings. Circulation. 2020;142(20):1925-36. Epub

2020/11/17. doi: 10.1161/CIRCULATIONAHA.120.046783. PubMed PMID: 33196309;

PubMed Central PMCID: PMCPMC7664968.

4.   Hwang IC, Kim CH, Kim JY, Choi HM, Yoon YE, Cho GY. Rate of Change in 10-

Year Atherosclerotic Cardiovascular Disease Risk and Its Implications for Primary

Prevention. Hypertension. 2023;80(8):1697-706. Epub 2023/07/20. doi:

10.1161/HYPERTENSIONAHA.122.20678. PubMed PMID: 37470768.

5.   Seong SC, Kim YY, Park SK, Khang YH, Kim HC, Park JH, et al. Cohort profile: the

National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in

Korea. BMJ Open. 2017;7(9):e016640. Epub 2017/09/28. doi: 10.1136/bmjopen-2017-

016640. PubMed PMID: 28947447; PubMed Central PMCID: PMCPMC5623538.

Figure Legend

Figure. Associations between changes in risk-factor status and ASCVD events.

The risk of ASCVD events is shown according to the increase (*left*) and decrease (*right*) in the number of risk factors between baseline and follow-up health screenings. Hazard ratios (HR) with 95% confidence intervals, calculated using multivariable Cox proportional hazard regression models, are depicted by rhombus marks (◆) for conventional calculation and square marks (■) for Firth's penalized likelihood procedures. ASCVD, atherosclerotic cardiovascular disease; HR, hazard ratio; yr, year

Risk of ASCVD according to the increase in the number of risk factors

No. of risk factors at baseline	Changes in risk factor status	Number of events / patients	Follow-up duration, yr
0	0 (Referenced)	48 / 5581	6.0
	+1	73 / 8190	5.9
	+2	33 / 2051	5.8
	+3	7 / 298	6.0
	+4	0 / 16	6.5
	+5 or 6	0 / 1	5.8
1	-1 (Referenced)	113 / 13589	5.9
	0	443 / 47577	5.8
	+1	179 / 15772	5.9
	+2	42 / 3107	5.9
	+3	6 / 340	5.7
	+4 or 5	1 / 20	4.2
2	-2 (Referenced)	55 / 4980	6.1
	-1	269 / 23302	6.0
	0	368 / 31424	6.0
	+1	136 / 10050	5.9
	+2	35 / 1607	6.0
	+3 or 4	0 / 131	5.9

Risk of ASCVD according to the decrease in the number of risk factors

No. of risk factors at baseline	Changes in risk factor status	Number of events / patients	Follow-up duration, yr
3	+2 or 3 (Referenced)	6 / 301	6.2
	+1	46 / 2589	6.0
	0	135 / 10605	5.9
	-1	160 / 12741	5.9
	-2	89 / 5996	5.7
	-3	14 / 1005	5.4
4	+1 or 2 (Referenced)	5 / 247	5.8
	0	15 / 1554	5.6
	-1	49 / 3040	5.7
	-2	37 / 2601	5.7
	-3	10 / 1020	5.6
	-4	1 / 138	5.5
5 or 6	0 or +1 (Referenced)	3 / 106	3.9
	-1	5 / 298	2.4
	-2	8 / 424	2.2
	-3	4 / 282	2.0
	-4	0 / 85	2.2
	-5	0 / 9	1.9

Adjusted HR for ASCVD event